PUBLIC HEALTH EVALUATION Clinical Trial
— SHAREOfficial title:
Impact of Task Shifting Type II for ART Delivery on Patient and Process Outcomes in Uganda
Verified date | January 2018 |
Source | Makerere University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
PUBLIC HEALTH EVALUATION PROTOCOL on Impact of Task Shifting Type II for ART Delivery on Patient and Process Outcomes in Uganda
Status | Completed |
Enrollment | 1760 |
Est. completion date | September 2017 |
Est. primary completion date | September 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Individuals will be eligible for the study if they: - are 18 years or older - have a confirmed HIV+ diagnosis at an accredited health facility according to the National HIV Testing Algorithm - are ART naive (except for short course mother-to-child transmission prophylaxis and post exposure prophylaxis not less than 6 months prior to study enrollment) - are clinically stable (no serious opportunistic infection, no other chronic condition) - are eligible for ART according to the Uganda National Treatment Guidelines Exclusion Criteria: - Individuals will not be eligible for the study if they - have more than grade 3 laboratory results for renal function, liver enzymes and hematology according to the National Institutes of Health Division of AIDS toxicity grading scale - are unwilling to give informed consent - anticipate moving from their current residence in the subsequent 24 months and - reside outside of a 40km radius (or more than 1 hour drive) of the selected study site. |
Country | Name | City | State |
---|---|---|---|
Uganda | Mbale Regional Referral Hospital | Mbale |
Lead Sponsor | Collaborator |
---|---|
Infectious Diseases Institute | Centers for Disease Control and Prevention, Ministry of Health, Uganda |
Uganda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Treatment-limiting events that could occur on first-line ART | The primary study outcome is a composite endpoint of possible treatment-limiting events that could occur on first-line ART. These include virologic failure (viral load measure of = 1000 copies/ml after 6 months of treatment), toxicity failure, loss to follow up and all-cause mortality. | 12 months |